abbv-20240725



UNITED STATES


SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549
 _____________________________________________________

FORM 8-K



CURRENT REPORT


Pursuant to Section 13 or 15(d) of the


Securities Exchange Act of 1934



Date of Report (Date of earliest event reported): July 25, 2024



ABBVIE INC.

(Exact name of registrant as specified in its charter)

|    |                              |                          |                     |
|---:|:-----------------------------|:-------------------------|:--------------------|
|  1 | Delaware                     | 001-35565                | 32-0375147          |
|  2 | (State or other Jurisdiction | (Commission File Number) | (IRS Employer       |
|  3 | of Incorporation)            |                          | Identification No.) |

 _____________________________________________________


1 North Waukegan Road


North Chicago, Illinois 60064-6400

(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code:  (847) 932-7900

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐                      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐                      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐                      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐                      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


|    |                               |                   |                                           |
|---:|:------------------------------|:------------------|:------------------------------------------|
|  1 | Title of each class           | Trading Symbol(s) | Name of each exchange on which registered |
|  2 | Common Stock, $0.01 Par Value | ABBV              | New York Stock Exchange                   |
|  3 |                               |                   | Chicago Stock Exchange                    |
|  5 | 0.750% Senior Notes due 2027  | ABBV27            | New York Stock Exchange                   |
|  6 | 2.125% Senior Notes due 2028  | ABBV28            | New York Stock Exchange                   |
|  7 | 2.625% Senior Notes due 2028  | ABBV28B           | New York Stock Exchange                   |
|  8 | 2.125% Senior Notes due 2029  | ABBV29            | New York Stock Exchange                   |
|  9 | 1.250% Senior Notes due 2031  | ABBV31            | New York Stock Exchange                   |



Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 2.02  Results of Operations and Financial Condition


On July 25, 2024, AbbVie Inc. issued a press release announcing financial results for the second quarter ended June 30, 2024.  A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits


(d) Exhibits


|    |             |                                                                                                         |
|---:|:------------|:--------------------------------------------------------------------------------------------------------|
|  1 | Exhibit No. | Exhibit                                                                                                 |
|  2 | 99.1        | Press Release dated July 25, 2024 (furnished pursuant to Item 2.02).                                    |
|  3 | 104         | The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). |


SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


|    |       |               |     |                           |
|---:|:------|:--------------|:----|:--------------------------|
|  1 |       |               |     | ABBVIE INC.               |
|  3 | Date: | July 25, 2024 | By: | /s/ Scott T. Reents       |
|  4 |       |               |     | Scott T. Reents           |
|  5 |       |               |     | Executive Vice President, |
|  6 |       |               |     | Chief Financial Officer   |


